Abstract
Lapatinib-loaded nanocolloidal polymeric micelles for the efficient treatment of breast cancer
Highlights
Breast cancer (BC), standing on the second rank for mortality, is predicted to cause about 2.4 million cases by 2025 among women (WHO, 2018)
The results of this study indicate the greater potential of LP-Polymeric micelles (PMs) for the efficient treatment for breast cancer (BC)
The size visualized by AFM was smaller than that found by dynamic laser scattering (DLS) in our previous studies
Summary
Breast cancer (BC), standing on the second rank for mortality, is predicted to cause about 2.4 million cases by 2025 among women (WHO, 2018). Human epidermal growth factor receptor 2 (HER2) expressing BC constitutes about 30% instances among the types of BC (Wei et al, 2015). LP is a dual inhibitor of Epidermal growth factor receptor (EGFR) and HER2 (Xia et al, 2002); its clinical use is limited due to its higher plasma protein binding (about 99%), high hydrophobicity, and poor aqueous solubility. LP is administered frequently, In the past few years, nanocolloidal systems, like Polymeric micelles (PMs), have been shown to be the most attractive nanocarriers for solubility and bioavailability improvement of hydrophobic drugs, owing to their unique core– shell structure (Bonde et al, 2018; Chiappetta and Sosnik, 2007; Guo et al, 2016). The particle size of PMs (
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
